JP2005535686A5 - - Google Patents

Download PDF

Info

Publication number
JP2005535686A5
JP2005535686A5 JP2004525348A JP2004525348A JP2005535686A5 JP 2005535686 A5 JP2005535686 A5 JP 2005535686A5 JP 2004525348 A JP2004525348 A JP 2004525348A JP 2004525348 A JP2004525348 A JP 2004525348A JP 2005535686 A5 JP2005535686 A5 JP 2005535686A5
Authority
JP
Japan
Prior art keywords
amine functional
matrix
tds
drug
functional drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004525348A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005535686A (ja
JP4837915B2 (ja
Filing date
Publication date
Priority claimed from EP02016864A external-priority patent/EP1386604A1/en
Application filed filed Critical
Publication of JP2005535686A publication Critical patent/JP2005535686A/ja
Publication of JP2005535686A5 publication Critical patent/JP2005535686A5/ja
Application granted granted Critical
Publication of JP4837915B2 publication Critical patent/JP4837915B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2004525348A 2002-07-30 2003-07-28 改善された経皮送達系 Expired - Lifetime JP4837915B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02016864A EP1386604A1 (en) 2002-07-30 2002-07-30 Improved transdermal delivery system
EP02016864.7 2002-07-30
PCT/EP2003/008319 WO2004012719A1 (en) 2002-07-30 2003-07-28 Improved transdermal delivery system

Publications (3)

Publication Number Publication Date
JP2005535686A JP2005535686A (ja) 2005-11-24
JP2005535686A5 true JP2005535686A5 (cg-RX-API-DMAC7.html) 2006-06-08
JP4837915B2 JP4837915B2 (ja) 2011-12-14

Family

ID=30011092

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004525348A Expired - Lifetime JP4837915B2 (ja) 2002-07-30 2003-07-28 改善された経皮送達系

Country Status (21)

Country Link
EP (2) EP1386604A1 (cg-RX-API-DMAC7.html)
JP (1) JP4837915B2 (cg-RX-API-DMAC7.html)
KR (1) KR101016914B1 (cg-RX-API-DMAC7.html)
CN (1) CN100558350C (cg-RX-API-DMAC7.html)
AT (1) ATE343380T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003266252B2 (cg-RX-API-DMAC7.html)
BR (1) BR0313092A (cg-RX-API-DMAC7.html)
CA (1) CA2490573C (cg-RX-API-DMAC7.html)
CY (1) CY1105878T1 (cg-RX-API-DMAC7.html)
DE (1) DE60309329T2 (cg-RX-API-DMAC7.html)
DK (1) DK1524971T3 (cg-RX-API-DMAC7.html)
ES (1) ES2273042T3 (cg-RX-API-DMAC7.html)
IL (1) IL165917A (cg-RX-API-DMAC7.html)
MX (1) MXPA05000349A (cg-RX-API-DMAC7.html)
NO (1) NO334187B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ537476A (cg-RX-API-DMAC7.html)
PL (1) PL376999A1 (cg-RX-API-DMAC7.html)
PT (1) PT1524971E (cg-RX-API-DMAC7.html)
SI (1) SI1524971T1 (cg-RX-API-DMAC7.html)
WO (1) WO2004012719A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200500255B (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
EP1386605A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
ES2661767T3 (es) 2008-02-27 2018-04-03 Hisamitsu Pharmaceutical Co., Inc. Parche adhesivo para la piel y producto envasado
JP5537412B2 (ja) 2008-02-27 2014-07-02 久光製薬株式会社 貼付製剤
WO2011076879A1 (en) * 2009-12-22 2011-06-30 Ucb Pharma Gmbh Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine
DE102011090178A1 (de) 2011-12-30 2013-07-04 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit geringer Neigung zur Spontankristallisation
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀(Rotigotine)之多天式貼片
CN105358139B (zh) 2013-07-03 2020-10-16 Lts罗曼治疗方法有限公司 具有电子元件的经皮治疗系统
ES2954087T3 (es) 2014-05-20 2023-11-20 Lts Lohmann Therapie Systeme Ag Sistema de administración transdérmica que incluye un mediador de interfase
CN106456567A (zh) 2014-05-20 2017-02-22 Lts勒曼治疗系统股份公司 在经皮递送系统中调节活性剂释放的方法
JP6573913B2 (ja) 2014-05-20 2019-09-11 エルテーエス ローマン テラピー−ジステーメ アーゲー ロチゴチンを含む経皮送達システム
DK3854388T3 (da) 2020-01-24 2023-11-27 Luye Pharma Switzerland Ag Transdermalt terapeutisk system omfattende rotigotin og mindst et ikke-aminresistent silikoneklæbestof
EP3949956A1 (en) * 2020-08-06 2022-02-09 LTS Lohmann Therapie-Systeme AG Esketamine-suspension-tts

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736577A (en) * 1995-01-31 1998-04-07 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
US5989586A (en) * 1992-10-05 1999-11-23 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
US5601839A (en) * 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE19814083C2 (de) * 1998-03-30 2002-02-07 Lohmann Therapie Syst Lts Verfahren zur Herstellung von transdermalen therapeutischen Systemen unter Verwendung von basischen Alkalimetallsalzen zur Umwandlung von Wirkstoffsalzen in die freien Basen
FR2792529B1 (fr) * 1999-04-26 2001-09-28 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques comprenant des derives de 2-isoxazole-8-aminotetralines
IT1311696B1 (it) * 1999-06-22 2002-03-19 Zanussi Elettromecc Compressore del fluido frigorigeno azionato da un motore elettricoa frequenza di alimentazione variabile
JP2002045699A (ja) * 2000-08-08 2002-02-12 Mitsubishi Electric Corp 排ガス浄化用層状電気化学触媒
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
DE10060550C1 (de) * 2000-12-06 2002-04-18 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten
CA2441064A1 (en) * 2001-03-16 2002-09-26 Andrx Corporation Controlled release sulfonylurea formulation
KR100904158B1 (ko) * 2001-03-16 2009-06-23 알자 코포레이션 펜타닐 투여용 경피성 패치
PT1256340E (pt) * 2001-05-08 2003-12-31 Sanol Arznei Schwarz Gmbh Sistema terapeutico transdermico aperfeicoado para o tratamento da doenca de parkinson
EP1386605A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine

Similar Documents

Publication Publication Date Title
JP2005535687A5 (cg-RX-API-DMAC7.html)
US10272125B2 (en) Transdermal delivery of cannabidiol with other active moieties including cannabinoids
KR900007178B1 (ko) 피부 약제 처치용 치료제의 제법
JP5695562B2 (ja) 安定化された経皮薬物送達システム
JP5564469B2 (ja) ロチゴチン投与のための改善された経皮送達系
ES2639294T3 (es) Parche de varios días para la administración transdérmica de rotigotina
US8246980B2 (en) Transdermal delivery system
JP6132407B2 (ja) ドネペジルを含有する経皮吸収製剤及びその製造方法
EP2291157A1 (en) Compositions and methods for the transdermal delivery of pharmaceutical compounds
KR20090009951A (ko) 항치매제를 포함하는 경피 흡수 제제
JP5906302B2 (ja) 作用剤層および作用剤変換層を含む経皮組成物
KR20040029021A (ko) 활성성분으로서 펜타닐을 함유하는 경피치료 시스템
AU2016244227B2 (en) Once-a-day replacement transdermal administration of fentanyl
BR112014016176B1 (pt) Sistema terapêutico transdérmico com uma baixa tendência de cristalização espontânea e método para a formação do mesmo
KR101016914B1 (ko) 향상된 경피 송달 시스템
Hadgraft et al. Passive transdermal drug delivery systems: recent considerations and advances
JP2008530139A (ja) Trpv1アゴニストを送達するための装置
KR20050099537A (ko) 활성 물질의 투과를 촉진시키기 위한 가열 용도에 적합한경피 치료 시스템, 및 이의 용도
CA2630675C (en) Transdermal therapeutic system for volatile and/or thermolabile substances
EP4192440B1 (en) Esketamine-suspension-tts
JP6984871B2 (ja) リバスチグミン経皮吸収型貼付製剤
EP3818976A1 (en) Structure
KR20160106181A (ko) 피부 투과 촉진 조성물, 경피 투여 제제 및 첩부 제제
HK1187817B (en) Transdermal compositions comprising an active agent layer and an active agent conversion layer
HK1187817A (en) Transdermal compositions comprising an active agent layer and an active agent conversion layer